STING1 and cancer: Due to the capability of STING to stimulate immune response, numerous STING agonists are currently being evaluated for their suitability as anticancer drugs in the field of cancer immunotherapy (summarized in [3,4]), and recent evidence indicates that the combination of STING agonists with STAT3 inhibitors can further enhance antitumor immunity [5].